- Home
- / Elevation Oncology
Elevation Oncology
Stock Price
$0.6
2024-10-29
Market Capitalization
$35.1 M
2024-10-29
Elevation Oncology Summary
Company Summary
- Overview
- Elevation Oncology is a biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers. Its product inhibits tumor growth driven by neuregulin-1 ( NRG1) fusions.
- Type
- Public
- Status
- Active
- Founded
- 2019
- HQ
- New York, NY, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Lori Hu, Director
Valerie Malyvanh Jansen, Chief Medical Officer
Tim Clackson, Director
LocationsView all
1 location detected
New York, NY HQ
United States
888 7th Ave 12th floor
Elevation Oncology Financials
Summary Financials
- Net income (Q1, 2025)
- ($14.2M)
- Cash (Q1, 2025)
- $60.5M
- EBIT (Q1, 2025)
- ($14.2M)
- Enterprise value
- $6.1M